Search results for "Epilepsies"

showing 10 items of 31 documents

The largest caucasian kindred with dentatorubral-pallidoluysian atrophy: A founder mutation in italy

2019

BACKGROUND: Dentatorubral-pallidoluysian atrophy is a hereditary neurodegenerative disease prevalently reported in Japan but rare in Caucasians. The objective of this study was to reconstruct the pedigree of Italian dentatorubral-pallidoluysian atrophy familial cases describing their clinical features. METHODS: We investigated 6 apparently unrelated dentatorubral-pallidoluysian atrophy families comprising a total of 51 affected individuals: 13 patients were clinically examined, and for 38 patients clinical data were collected from clinical sources. The dentatorubral-pallidoluysian atrophy diagnosis was genetically confirmed in 18 patients. Genealogical data from historical archives were ana…

0301 basic medicineAdultMalePediatricsmedicine.medical_specialtyAdolescentDiseaseNeuropsychological TestsWhite People03 medical and health sciencesEpilepsyYoung Adult0302 clinical medicineAtrophyTrinucleotide Repeatsdentatorubral-pallidoluysian atrophymedicineHumansFamilyATN1 geneChildFounder mutationAgedDentatorubral-pallidoluysian atrophyEpilepsybusiness.industrygenealogical methodMiddle Agedmedicine.diseaseMyoclonic Epilepsies ProgressivePedigree030104 developmental biologyfounder effectNeurologyCerebellar cognitive affective syndromeItalycerebellar cognitive-affective syndromeMutationFemaleNeurology (clinical)business030217 neurology & neurosurgeryFounder effect
researchProduct

Antiepileptic drug reduction and increased risk of stimulation-evoked focal to bilateral tonic-clonic seizure during cortical stimulation in patients…

2017

Introduction: Stimulation-evoked focal to bilateral tonic-clonic seizure (FBTCS) can be a stressful and possibly harmful adverse event for patients during cortical stimulation (CS). We evaluated if drug load reduction of anti epileptic drugs (AEDs) during CS increases the risk of stimulation-evoked FBTCS. Material and methods: In this retrospective cohort study, we searched our local database for patients with drug resistant epilepsy who underwent invasive video-EEG monitoring and CS in the University Hospital la Fe Valencia from January 2006 to November 2016. The AED drug load was calculated with the defined daily dose. We applied a uni- and multivariate logistic regression model to estima…

0301 basic medicineAdultMalemedicine.medical_specialtyDrug Resistant EpilepsyNeurologyAdolescentDrug-Related Side Effects and Adverse ReactionsStimulation03 medical and health sciencesBehavioral NeuroscienceEpilepsy0302 clinical medicineEpilepsy surgerySeizuresmedicineOdds RatioHumansEpilepsy surgeryAdverse effectRetrospective Studiesbusiness.industryRetrospective cohort studyElectroencephalographyOdds ratioMiddle Agedmedicine.diseaseElectric Stimulation030104 developmental biologyDefined daily doseLogistic ModelsTreatment OutcomeNeurologyElectrical stimulationWithdrawalAnesthesiaDefined daily doseAnticonvulsantsEpilepsy GeneralizedFemaleNeurology (clinical)Epilepsies PartialEpilepsy Tonic-ClonicSafetybusinessGeneralized tonic-clonic seizure030217 neurology & neurosurgeryEpilepsybehavior : EB
researchProduct

Compassionate use of everolimus for refractory epilepsy in a patient with MTOR mosaic mutation

2020

Abstract The MTOR gene encodes the mechanistic target of rapamycin (mTOR), which is a core component of the PI3K-AKT-mTOR signaling pathway. Postzygotic MTOR variants result in various mosaic phenotypes, referred to in OMIM as Smith-Kinsgmore syndrome or focal cortical dysplasia. We report here the case of a patient, with an MTOR mosaic gain-of-function variant (p.Glu2419Lys) in the DNA of 41% skin cells, who received compassionate off-label treatment with everolimus for refractory epilepsy. This 12-year-old-girl presented with psychomotor regression, intractable seizures, hypopigmentation along Blaschko's lines (hypomelanosis of Ito), asymmetric regional body overgrowth, and ocular anomali…

0301 basic medicineOncologyCompassionate Use Trialsmedicine.medical_specialty[SDV]Life Sciences [q-bio]030105 genetics & heredityMuscle hypertrophyCraniofacial Abnormalities03 medical and health sciencesInternal medicineGeneticsmedicineHumansEverolimusChildMechanistic target of rapamycinProtein Kinase InhibitorsGenetics (clinical)PI3K/AKT/mTOR pathwayHypopigmentationEverolimusbiologybusiness.industryMosaicismTOR Serine-Threonine KinasesNeuropsychologyGeneral MedicineCortical dysplasiamedicine.disease3. Good healthClinical trialMalformations of Cortical Development[SDV] Life Sciences [q-bio]030104 developmental biologyPhenotypeGain of Function Mutationbiology.proteinFemaleEpilepsies Partialmedicine.symptombusinessmedicine.drug
researchProduct

A novel GABRB3 variant in Dravet syndrome: Case report and literature review

2020

Abstract Background Mutations in GABRB3 have been identified in subjects with different types of epilepsy and epileptic syndromes, including West syndrome (WS), Dravet syndrome (DS), Lennox‐Gastaut syndrome (LGS), myoclonic‐atonic epilepsy (MAE), and others. Methods and results We herewith report on a girl affected by DS, who has been followed from infancy to the current age of 18 years. Next‐generation sequencing (NGS)‐based genetic testing for multigene analysis of neurodevelopmental disorders identified two likely de novo pathogenic mutations, a missense variant in GABRB3 gene (c.842 C>T; p.Thr281IIe) and a nonsense variant found in BBS4 gene (c.883 C>T; p.Arg295Ter). Conclusion A likely…

0301 basic medicinelcsh:QH426-470media_common.quotation_subjectNonsenseMutation MissenseEpilepsies Myoclonic030105 genetics & hereditymedicine.disease_causeClinical ReportsBBS4 gene03 medical and health sciencesEpilepsyDravet syndromeGeneticsMedicineMissense mutationHumansMolecular BiologyGeneGenetics (clinical)media_commonGenetic testingGeneticsMutationClinical Reportmedicine.diagnostic_testbusiness.industryGABRB3 GeneEpileptic EncephalopathiesWest Syndromemedicine.diseaseReceptors GABA-ADravet syndromelcsh:Genetics030104 developmental biologyPhenotypeCodon NonsenseChild PreschoolFemalebusinessMicrotubule-Associated Proteins
researchProduct

Sustained seizure freedom with adjunctive brivaracetam in patients with focal onset seizures

2022

The maintenance of seizure control over time is a clinical priority in patients with epilepsy. The aim of this study was to assess the sustained seizure frequency reduction with adjunctive brivaracetam (BRV) in real-world practice. Patients with focal epilepsy prescribed add-on BRV were identified. Study outcomes included sustained seizure freedom and sustained seizure response, defined as a 100% and a ≥50% reduction in baseline seizure frequency that continued without interruption and without BRV withdrawal through the 12-month follow-up. Nine hundred ninety-four patients with a median age of 45 (interquartile range = 32-56) years were included. During the 1-year study period, sustained se…

AdultFreedomfocal seizuresEpilepsiesSettore MED/26Double-Blind MethodDrug Therapyantiseizure medication; brivaracetam; focal seizures; seizure freedom; sodium channel blockers; Adult; Double-Blind Method; Drug Therapy Combination; Freedom; Humans; Middle Aged; Pyrrolidinones; Seizures; Treatment Outcome; Anticonvulsants; Epilepsies PartialSeizuresseizure freedomHumansanti-seizure medication; focal seizures; epilepsyantiseizure medicationbrivaracetamanti-seizure medicationMiddle AgedPyrrolidinonesTreatment OutcomeNeurologysodium channel blockersCombinationepilepsyDrug Therapy CombinationAnticonvulsantsNeurology (clinical)Epilepsies PartialPartial
researchProduct

Do neurologists agree in diagnosing drug resistance in adults with focal epilepsy?

2019

Objective: To evaluate interrater agreement in categorizing treatment outcomes and drug responsiveness status according to the International League Against Epilepsy (ILAE) definition of drug-resistant epilepsy. Methods: A total of 1053 adults with focal epilepsy considered by the investigators to meet ILAE criteria for drug resistance were enrolled consecutively at 43 centers and followed up prospectively for 18-34 months. Treatment outcomes for all antiepileptic drugs (AEDs) used up to enrollment (retrospective assessment), and on an AED newly introduced at enrollment, were categorized by individual investigators and by 2 rotating members of a 16-member expert panel (EP) that reviewed the …

AdultMale0301 basic medicineDrug Resistant Epilepsymedicine.medical_specialtyPediatricsNeurologyAttitude of Health PersonnelTreatment outcomeantiepileptic drugs; classification; drug-resistant epilepsy; epilepsy; ILAE definition; reliability; Neurology; Neurology (clinical)Drug resistance03 medical and health sciencesEpilepsyantiepileptic drug0302 clinical medicinedrug-resistant epilepsymedicineHumansNeurologistsProspective Studiesantiepileptic drugsCooperative Behaviorreliabilitybusiness.industryMiddle Agedmedicine.diseaseDrug Resistant EpilepsyConfidence intervalInter-rater reliability030104 developmental biologyclassificationNeurologyepilepsyAnticonvulsantsFemaleEpilepsies PartialNeurology (clinical)businessILAE definition030217 neurology & neurosurgeryKappa
researchProduct

Breakdown of Thalamo-Cortical Connectivity Precedes Spike Generation in Focal Epilepsies

2017

Electroencephalography (EEG) spikes and focal epileptic seizures are generated in circumscribed cerebral networks that have been insufficiently described. For precise time and spatial domain network characterization, we applied in patients with focal epilepsy dense array 256-channel EEG recordings with causal connectivity estimation by using time-resolved partial directed coherence and 3T-magnetic resonance imaging-derived cortical and thalamus integrity reconstruction. Before spike generation, significant theta and alpha bands driven information flows alterations were noted from both temporal and frontal lobes to the thalamus and from the thalamus to the frontal lobe. Medial dorsal and ven…

AdultMale0301 basic medicineThalamusAction PotentialsElectroencephalographySensitivity and Specificity03 medical and health sciencesEpilepsy0302 clinical medicineThalamusBiological ClocksNeural PathwaysConnectomemedicineHumansIn patientFocal EpilepsiesCerebral CortexDense arraymedicine.diagnostic_testGeneral NeuroscienceReproducibility of ResultsElectroencephalographymedicine.disease030104 developmental biologyThalamo corticalFrontal lobeFemaleEpilepsies PartialNerve NetPsychologyNeuroscience030217 neurology & neurosurgeryBrain Connectivity
researchProduct

Correction to: Adjunctive Brivaracetam in Focal Epilepsy: Real‑World Evidence from the BRIVAracetam add‑on First Italian netwoRk Study (BRIVAFIRST)

2021

In randomized controlled trials, add-on brivaracetam (BRV) reduced seizure frequency in patients with drug-resistant focal epilepsy. Studies performed in a naturalistic setting are a useful complement to characterize the drug profile.This multicentre study assessed the effectiveness and tolerability of adjunctive BRV in a large population of patients with focal epilepsy in the context of real-world clinical practice.The BRIVAFIRST (BRIVAracetam add-on First Italian netwoRk STudy) was a retrospective, multicentre study including adult patients prescribed adjunctive BRV. Patients with focal epilepsy and 12-month follow-up were considered. Main outcomes included the rates of seizure-freedom, s…

AdultMaleDrug Resistant EpilepsyLevetiracetamEpilepsy CNS therapyCorrectionMiddle AgedSettore MED/26PyrrolidinonesPsychiatry and Mental healthTreatment OutcomeItalyChemotherapy AdjuvantHumansPharmacology (medical)AnticonvulsantsFemaleNeurology (clinical)Epilepsies PartialRetrospective Studies
researchProduct

Low-frequency transcranial magnetic stimulation in patients with cortical dysplasia: A preliminary study

2003

no abstract available

AdultMaleDrug Therapy CombinationFemaleElectric Stimulation TherapyPilot ProjectEpilepsies PartialTranscranial Magnetic StimulationHuman
researchProduct

Combined EEG and MEG analysis of early somatosensory evoked activity in children and adolescents with focal epilepsies

2006

Abstract Objective The study aimed to evaluate differences between EEG and MEG analysis of early somatosensory evoked activity in patients with focal epilepsies in localizing eloquent areas of the somatosensory cortex. Methods Twenty-five patients (12 male, 13 female; age 4–25 years, mean 11.7 years) were included. Syndromes were classified as symptomatic in 17, idiopathic in 2 and cryptogenic in 6 cases. 10 patients presented with malformations of cortical development (MCD). 122 channel MEG and simultaneous 33-channel EEG were recorded during tactile stimulation of the thumb (sampling rate 769 Hz, band-pass 0.3–260 Hz). Forty-four hemispheres were analyzed. Hemispheres were classified as t…

AdultMalemedicine.medical_specialtyAdolescentAudiologyElectroencephalographySomatosensory systemLesionEvoked Potentials SomatosensoryPhysical StimulationPhysiology (medical)Cortex (anatomy)medicineHumansChildCerebral CortexSensory stimulation therapymedicine.diagnostic_testMagnetoencephalographyElectroencephalographyMagnetoencephalographyMagnetic Resonance ImagingCentral sulcusSensory SystemsElectrophysiologymedicine.anatomical_structureNeurologyTouchChild PreschoolFemaleEpilepsies PartialNeurology (clinical)medicine.symptomPsychologyNeuroscienceClinical Neurophysiology
researchProduct